30 results
8-K
EX-99.2
CCCC
C4 Therapeutics, Inc.
9 Dec 24
Other Events
9:49am
of innovative therapies across treatment lines.”
Multiple Myeloma (MM)
At the ASH Annual Meeting, C4T presented safety and anti-myeloma data demonstrating
8-K
EX-99.3
CCCC
C4 Therapeutics, Inc.
9 Dec 24
Other Events
9:49am
of Clinical Updates and Innovative Collaborations Over the Past 12 Months… Cemsidomide Collaborations Have Further Validated TORPEDO Platform CFT1946
8-K
EX-99.1
CCCC
C4 Therapeutics, Inc.
9 Dec 24
Other Events
9:49am
and Innovative Collaborations Over the Past 12 Months… Cemsidomide Collaborations Have Further Validated TORPEDO Platform CFT1946 CFT8919 Significant Progress
8-K
EX-99.1
CCCC
C4 Therapeutics, Inc.
20 Nov 24
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
7:11am
advancing oncology programs into the commercial market will help guide our plans to become a fully integrated biotechnology company bringing innovative
8-K/A
EX-99.1
CCCC
C4 Therapeutics, Inc.
15 Oct 24
Departure of Directors or Certain Officers
5:53pm
to join C4 Therapeutics at this exciting time as we focus on opportunities to leverage our innovative science and further extend our leadership
8-K
EX-99.1
u9o6bbsc6yp 5jz
15 Oct 24
Departure of Directors or Certain Officers
4:11pm
8-K
EX-99.1
dttq84byn48x aj92u
3 Sep 24
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
7:06am
8-K
EX-99.1
qc3p5d
8 May 24
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
7:07am
ARS
tv3dsj65xsp6235lfsl
30 Apr 24
Annual report to shareholders
8:52am
8-K
EX-99.1
qlmi oeapnr7nxbn
30 May 23
Entry into a Material Definitive Agreement
7:30am
ARS
erkggttpl8z7
28 Apr 23
Annual report to shareholders
7:03am
8-K
EX-99.1
jph3xi f3
2 Aug 22
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors
8:33am
8-K
EX-99.1
5yq1j 3tyd67lsr
10 Nov 21
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
4:12pm
424B4
u0jc602qr3i8bmnrt3cn
21 Jun 21
Prospectus supplement with pricing info
8:08am